Jayson L. Parker

1.2k total citations
34 papers, 967 citations indexed

About

Jayson L. Parker is a scholar working on Economics and Econometrics, Statistics and Probability and Immunology. According to data from OpenAlex, Jayson L. Parker has authored 34 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Economics and Econometrics, 11 papers in Statistics and Probability and 8 papers in Immunology. Recurrent topics in Jayson L. Parker's work include Statistical Methods in Clinical Trials (11 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Jayson L. Parker is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Biosimilars and Bioanalytical Methods (8 papers). Jayson L. Parker collaborates with scholars based in Canada, United States and Brazil. Jayson L. Parker's co-authors include Constantine X. Poulos, Anh D. Lê, Sandra E. Black, John Paul Szalai, M. J. Bronskill, Christine A. Szekely, Gilberto Lopes, Jonathan O. Dostrovsky, Morris Moscovitch and Daphne Kidron and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and NeuroImage.

In The Last Decade

Jayson L. Parker

32 papers receiving 950 citations

Peers

Countries citing papers authored by Jayson L. Parker

Since Specialization

Citations

This map shows the geographic impact of Jayson L. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayson L. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayson L. Parker more than expected).

Fields of papers citing papers by Jayson L. Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayson L. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayson L. Parker. The network helps show where Jayson L. Parker may publish in the future.

Co-authorship network of co-authors of Jayson L. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Jayson L. Parker. A scholar is included among the top collaborators of Jayson L. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayson L. Parker. Jayson L. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Agentic Medical Knowledge Graphs Enhance Medical Question Answering: Bridging the Gap Between LLMs and Evolving Medical Knowledge 2025 ·(unknown), (unknown), Jayson L. Parker, Rahul G. Krishnan, Milad Lankarany	0
2	The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs 2022 ·The Oncologist ·(unknown), (unknown), (unknown), (unknown), Gilberto Lopes, Jayson L. Parker	0
3	Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis 2021 ·Cancer Medicine ·Jayson L. Parker, (unknown), (unknown), Stephen Mac, Gilberto Lopes, (unknown), Ashini Weerasinghe, (unknown), (unknown), Ayşe Bener, Bora Çağlayan, (unknown), Nicholas Mitsakakis	24
4	Clinical trial risk in leukemia: Biomarkers and trial design 2020 ·Hematological Oncology ·Alice Li, (unknown), Gilberto Lopes, Jayson L. Parker	5
5	Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria 2015 ·Respiration ·(unknown), Jayson L. Parker, (unknown), Meyer Balter	5
6	Reducing clinical trial risk in multiple sclerosis 2015 ·Multiple Sclerosis and Related Disorders ·(unknown), Jayson L. Parker, Paul O’Connor, (unknown)	8
7	Clinical Trial Risk in Type-2 Diabetes: Importance of Patient History 2014 ·Journal of Pharmacy & Pharmaceutical Sciences ·(unknown), Jay Silverberg, Safina Ali, Jayson L. Parker	3
8	Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·(unknown), Gilberto Lopes, Jayson L. Parker	31
9	Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines 2013 ·Vaccine ·Ayman Chit, Jayson L. Parker, Scott A. Halperin, (unknown), Murray Krahn, Paul Grootendorst	14
10	Impact of biomarkers on clinical trial risk in breast cancer 2012 ·Breast Cancer Research and Treatment ·Jayson L. Parker, (unknown), (unknown), Teresa M. Petrella, Rebecca Dent, Gilberto Lopes	26
11	Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis 2012 ·The Journal of Rheumatology ·(unknown), Edward Keystone, Jayson L. Parker	13
12	Clinical Trial Risk in Non-Hodgkin’s Lymphoma: Endpoint and Target Selection 2011 ·Journal of Pharmacy & Pharmaceutical Sciences ·Jayson L. Parker, (unknown), Rena Buckstein	17
13	The Success Rate of New Drug Development in Clinical Trials: Crohn’s Disease 2010 ·Journal of Pharmacy & Pharmaceutical Sciences ·Jayson L. Parker, Jillian Clare Köhler	21
14	Callosal Atrophy Correlates with Temporal Lobe Volume and Mental Status in Alzheimer's Disease 2000 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Sandra E. Black, Scott D. Moffat, David C. Yu, Jayson L. Parker, Peter Stanchev, Michael Bronskill	28
15	Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer’s disease 1998 ·Neuropsychologia ·Stefan Köhler, Sandra E. Black, (unknown), Christine A. Szekely, Daphne Kidron, Jayson L. Parker, Jonathan K. Foster, Morris Moscovitch, (unknown), John Paul Szalai, M. J. Bronskill	183
16	Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus 1997 ·Brain Research ·Anuradha Mathur, (unknown), Steven R. Laviolette, Jayson L. Parker, John S. Yeomans	58
17	Quantitative MR volumetry in Alzheimer's disease 1997 ·Neurology ·Debora Kidron, Sandra E. Black, Peter Stanchev, Brian Buck, John Paul Szalai, Jayson L. Parker, Christine A. Szekely, M. J. Bronskill	93
18	Dexfenfluramine and 8-OH-DPAT modulate impulsivity in a delay-of-reward paradigm 1996 ·Behavioural Pharmacology ·Constantine X. Poulos, Jayson L. Parker, Anh D. Lê	58
19	Can MRI brain measures distinguish alzheimer's disease from normal aging? 1996 ·NeuroImage ·Sandra E. Black, Christine A. Szekely, John Paul Szalai, Daphne Kidron, Dian Yu, Jayson L. Parker, Brian Buck, Peter Stanchev, M. J. Bronskill	1
20	Tegmental pedunculopontine nucleus lesions do not block cocaine reward 1995 ·Pharmacology Biochemistry and Behavior ·Jayson L. Parker, Derek van der Kooy	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact